Details of Drug-Drug Interaction
| Drug General Information (ID: DDIFX2UDN1) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug Name | Nicotinamide | Drug Info | Calaspargase pegol | Drug Info | |||||
| Drug Type | Small molecule | Monoclonal antibody | |||||||
| Therapeutic Class | Antiinflammatory Agents | Antineoplastics | |||||||
| Mechanism of Nicotinamide-Calaspargase pegol Interaction (Severity Level: Moderate) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Increased risk of hepatotoxicity Click to Show/Hide Mechanism Graph | |||||||||
 |
|||||||||
| Drug Name | Nicotinamide | Calaspargase pegol | |||||||
| Mechanism | Hepatotoxicity | Hepatotoxicity | |||||||
| Key Mechanism Factor 1 | |||||||||
| Factor Name | Hepatotoxicity | ||||||||
| Factor Description | Combination of drugs that can induce hepatotoxicity may increase the risk of liver injury. Symptoms vary depending on the level of exposure and the total extent of liver damage, and may cause few symptoms if the damage is mild, and eventually lead to liver failure in patients with severe damage. | ||||||||
| Mechanism Description |
|
||||||||
| Recommended Action | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Management | The risk of additive hepatotoxicity should be considered when asparaginase is used with other hepatotoxic agents (e.g., alcohol, androgens, antituberculosis agents, azole antifungal agents, ACE inhibitors, macrolide antibiotics, nonsteroidal anti-inflammatory agents, nucleoside reverse transcriptase inhibitors, sulfonamides, thiazolidinediones, and statins). Liver function tests should be monitored at regular intervals during asparaginase treatment with or without other hepatotoxic drugs. Patients should be advised to seek medical attention if they experience potential symptoms of hepatotoxicity such as right upper quadrant pain, increasing abdominal size, fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, dark urine, pale stools, and jaundice. | ||||||||